Company's Comprehensive Drug Portfolio Further Expands with Addition of Two Leading Products
NEW YORK, Jan 05, 2015 (BUSINESS WIRE) -- Onco360, one of the nation's largest independent providers of Oncology Pharmacy services, today announced that it has been selected by Bayer AG ("Bayer") as a limited distribution pharmacy network participant for two of its leading oncology medications, Nexavar® (sorafenib) and Stivarga® (regorafenib). With the addition of these two medications, Onco360's industry-leading oncology medication portfolio now comprises nearly 40 limited distribution products.
Both of the new additions to Onco360's portfolio have been approved by the U.S. Food and Drug Administration (FDA) as targeted therapies in comprehensive cancer treatment and are immediately available for order through Onco360.
Nexavar is a kinase inhibitor approved for the treatment of:
Unresectable hepatocellular carcinoma;
Advanced renal cell carcinoma; and
Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Stivarga is a kinase inhibitor approved for the treatment of patients with:
Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy; and
Locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST) that have been previously treated with imatinib mesylate and sunitinib malate.
"This relationship with Bayer marks another significant step forward in Onco360's mission to transform cancer treatment and promote the highest standards of patient care," said Paul Jardina, President and Chief Executive Officer of Onco360. "This selection also underscores the success we continue to have advancing our unique and comprehensive approach to oncology pharmacy services. We will continue to work with global pharmaceutical manufacturers to expand our care platform and broaden our clinical support services."
"Today's announcement further demonstrates our commitment to providing the greatest depth and breadth of oncology pharmacy products possible to support patients and their physicians in the fight against cancer," said Burt Zweigenhaft, Vice Chairman and Chief Strategy Officer of Onco360. "Nexavar and Stivarga are best-in-class products and important additions to our product portfolio. We are excited to be advancing our patient-centric mission by bringing these innovative therapies to the people that need them the most."
Both Nexavar and Stivarga products are immediately available for order through Onco360. Information on how to order can be obtained by visiting www.Onco360.com/Order. For more information about Onco360 please visit www.Onco360.com.
About Onco360®, Oncology Pharmacy Solutions:
With executive offices in New York City, Onco360 (http://onco360.com) is the largest independent provider of Oncology Pharmacy services in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. The company's clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients. Onco360 is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and the clinical experience and expertise that comes from its focus in oncology. Onco360 dispenses through its network JCAHO-accredited Oncology Pharmacies. PharMerica Corporation (NYSE:PMC), a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, made a significant strategic investment in Onco360. The partnership between PharMerica and Onco360 creates the only national oncology pharmacy and care management platform in the country, with the unique ability to service the localized needs of community- and hospital based-oncologists.